About Bukwang Pharmaceutical
Bukwang Pharmaceutical is a company based in South Korea. It operates as a HealthTech and Direct-to-Consumer (D2C). Bukwang Pharmaceutical has raised $5.2 million across 1 funding round from investors including TVM Capital Life Science. Bukwang Pharmaceutical has completed 1 acquisition, including Korea Union Pharmaceuticals. Bukwang Pharmaceutical offers products and services including Lurasidone, JM-010, SOL-804, and Legadex.
- Headquarter South Korea
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Bukwang Pharm Co., Ltd.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$5.2 M (USD)
in 1 rounds
-
Latest Funding Round
$5.2 M (USD), Series A
Mar 29, 2017
- Investors
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Bukwang Pharmaceutical
Bukwang Pharmaceutical offers a comprehensive portfolio of products and services, including Lurasidone, JM-010, SOL-804, and Legadex.
Used for treating schizophrenia and bipolar depression effectively.
Developed for treating dyskinesia in Parkinson’s disease patients.
Designed for metastatic castration-resistant prostate cancer treatment.
Formulated as a liver disease treatment compound drug.
People of Bukwang Pharmaceutical
Unlock access to complete
Unlock access to complete
Funding Insights of Bukwang Pharmaceutical
Bukwang Pharmaceutical has successfully raised a total of $5.2M through 1 strategic funding round. The most recent funding activity was a Series A round of $5.2 million completed in March 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Bukwang Pharmaceutical
Bukwang Pharmaceutical has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include TVM Capital Life Science.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life Science focused early stage VC firm investing in Europe, Canada, the USA and Asia
|
Locked | Locked | Locked |
Investor details for Bukwang Pharmaceutical
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Bukwang Pharmaceutical
Bukwang Pharmaceutical has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Korea Union Pharmaceuticals.
Investment portfolio details for Bukwang Pharmaceutical
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Utility industry construction, inspection, and maintenance services are provided.
|
Locked | Locked | 1956 | Locked |
Complete acquisition details for Bukwang Pharmaceutical
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Bukwang Pharmaceutical
Detailed financials for Bukwang Pharmaceutical
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Bukwang Pharmaceutical Comparisons
Peer comparison for Bukwang Pharmaceutical
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Bukwang Pharmaceutical
Detailed competitors of Bukwang Pharmaceutical
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bukwang Pharmaceutical
Complete news archive for Bukwang Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bukwang Pharmaceutical
Bukwang Pharmaceutical is headquartered in South Korea.
Bukwang Pharmaceutical is a funded company, having raised a total of $5.2M across 1 funding round to date.
Bukwang Pharmaceutical is involved in the research, development, and production of pharmaceutical products, including prescription medicines, over-the-counter drugs, and health supplements. The company operates in the healthcare sector, focusing on innovative drug development for conditions such as schizophrenia, Parkinsons disease, and prostate cancer. Solutions are provided through a robust pipeline and open innovation strategies, aiming for global expansion as a leading pharmaceutical entity. Emphasis is placed on sustainability and ethical governance to ensure a healthier future.
Bukwang Pharmaceutical offers Lurasidone, JM-010, SOL-804, and Legadex.
Bukwang Pharmaceutical has made 1 acquisition, including Korea Union Pharmaceuticals.
Bukwang Pharmaceutical has 1 investor. Key investors include TVM Capital Life Science.